Can we eliminate placebo in ALS clinical trials?

WW Bryan Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA

RJ Hoagland Syntex‐Synergen Neuroscience Joint Venture, USA

J Murphy Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver, Colorado, USA

C Armon Department of Neurology, Loma Linda University School of Medicine, Loma Linda, California, USA

RJ Barohn Department of Neurology, California Pacific Medical Center, Forbes Norris MDA/ALS Center, San Francisco, California, USA

JC Goodpasture Department of Neurology, University of Minnesota School of Medicine, Minneapolis, Minnesota, USA

RG Miller Department of Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USA

GJ Parry Department of Neurology, University of Kentucky, Lexington, Kentucky, USA

JH Petajan The participants and their institutions are listed in the Appendix at the end of this article.

MA Ross Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA

SC Stromatt Syntex‐Synergen Neuroscience Joint Venture, USA

References